logo
Plus   Neg
Share
Email

Pfizer Initiates Phase 2 Trial Of BCMA-CD3 Bispecific Antibody Elranatamab In Multiple Myeloma

Pfizer Inc. (PFE) said Wednesday that the first participant has been dosed in the registration-enabling Phase 2 MagnetisMM-3 study or NCT04649359 of elranatamab or PF-06863135, an investigational B-cell maturation antigen or BCMA CD3-targeted bispecific antibody, in patients with relapsed/refractory multiple myeloma.

The study evaluates the efficacy and safety of elranatamab, administered subcutaneously, in patients with disease that is refractory to at least one agent in each of three major classes of medications approved for multiple myeloma. The study's estimated primary completion date is June 2022.

The U.S. Food and Drug Administration has granted Fast Track Designation to elranatamab.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
CVS Pharmacy, the retail division of CVS Health, announced the availability of three over-the-counter or OTC COVID-19 testing options in stores and online. With these new-to-market home tests, customers will get access to convenient testing that can be conducted at home. The tests include the Ellume COVID-19 Home Test, the Abbott BinaxNOW COVID-19 Antigen Self Test and the Pixel by Labcorp PCR Tes United Airlines is adding three new flights to Croatia, Greece and Iceland, which are starting to reopen to vaccinated visitors. The move would give travelers more options for summer travel by flying direct to these countries. Last month's searches on United.com for flights to Croatia, Greece and Iceland were up 61 percent. Johnson & Johnson's (JNJ) Covid-19 vaccine is expected to be back on track as early as this weekend as a decision is expected after the advisory panel meeting of the U.S. Centers for Disease Control and Prevention (CDC) slated on April 23, according to Dr. Anthony Fauci, the chief medical adviser to President Joe Biden.
Follow RTT